Connect with us

BUSINESS

Cara Therapeutics Inc (NASDAQ:CARA) Will Report Topline Data Of Pivotal KALM-2 Phase 3 Trial Of KORSUVA Injection In Q2 2020: Will Submit NDA For KORSUVA Injection To FDA

Published

on

Cara Therapeutics Inc (NASDAQ:CARA) is on track to provide topline data for the pivotal KALM-2 Phase 3 clinical trial of KORSUVA injection in Q2 2020. The company is conducting phase 3 clinical trial of KORSUVA injection in hemodialysis patients suffering from CKD-ap. It will also submit NDA (New Drug Application) for KORSUVA injection to the US FDA in Q2.

CEO and President of Cara, Derek Chalmers said under the updated guidance of the FDA the company is on track to report topline data from KALM-2 in Q2 despite the ongoing coronavirus crisis. He further said the company is making significant progress in phase 3 clinical trial of KORSUVA injection that comprises supportive safety data.

Evaluates Oral KORSUVA for atopic dermatitis

Cara is conducting phase 2 clinical trials on oral KORSUVA for the treatment of atopic dermatitis in patients suffering from moderate to severe pruritus, and patients suffering from hepatic impairment due to PBC (primary biliary cholangitis), and patients with pruritus. The company will conclude an interim statistical analysis in Q2 for the ongoing phase 2 trial in patients with atopic dermatitis. It will present the data from the previous positive phase 2 dose clinical trial of Oral KORSUVA to cure pruritus in patients suffering from moderate to severe CKD at the National Kidney Foundation Spring Clinical Meeting.

KALM-2 phase 3 clinical trial

The placebo-controlled, randomized, multicenter 12-week phase 2 trial evaluates the efficacy and safety of 0.5 mcg/kg KORSUVA injection in four hundred thirty patients suffering from moderate to severe pruritus. In the primary efficacy end-point, a proportion of the patients should at least achieve a three-point improvement in the weekly mean data of the 24‑hour Worst Itching Intensity Numeric Rating Scale daily at the end of week 12.

Cara has reported the topline data from phase 3 KALM-1 US trials in May 2019. It has achieved the primary end-point along with a significant improvement. The trial also accomplished the secondary end-point and the patients have well tolerated the KORSUA injection during a 12-week treatment.

Cara is pleased to announce that Derek will take part in the 19th Annual Needham Healthcare Conference on April 15, 2020. The investors can access web recording from its website.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.

BUSINESS

Neuropsychiatry Expert Dr. Ilya Reznik (MD) Joins Cannabics as Head of Psychedelic Inspired Medicine

Published

on

Cannabics Pharmaceuticals Inc (OTCMKTS: CNBX), a global head in developing cannabinoid-based cancer-related medicine and a settler in the development of psychedelic-inspired medicine, stated today that Dr. Ilya Reznik (MD), an eminent Neuropsychiatrist, has joined Cannabics as Head of Psychedelic Inspired Medicine.

The selection of Dr. Reznik is a part of the company’s plan to develop new psychedelic inspired medicines and therapies to focus on several mental health-related conditions. The declarations made to the company’s recent initiation of a Psilocybin and Psilocin Research Program are taking place under the approval of the Israeli Ministry of Health.

Management Statement

Eyal Barad, Cannabics Pharmaceuticals’ CEO, stated that “I am glad to announce that I introduced Dr. Reznik to our team. Dr. Reznik is a world-renowned Neuropsychiatrist with great experience and accomplishments in his field of specialty and conducted extensive research using psychedelic compounds. I look forward to working with Reznik, and I am indeed confident about his initiative of driving the company’s psychedelic inspired development program successfully.”

Dr. Ilya Reznik’s Statement

Dr. Ilya Reznik further stated that” It is a great pleasure to have been introduced in the team of Cannabics Pharmaceuticals, a well-known performer in the field of cannabinoid-based medicine development. The company’s well established existing facilities, experience and helps to build an excellent foundation upon which we will now initiate a new development program for Psychedelic Inspired Medicine.  I love working with the Cannabics in making this an indeed successful venture that could assist large groups of patients suffering from different mental conditions with undone needs.”

Moreover, Reznik gained extensive research experience in cannabis and its based products during the last 12 years. He was appointed as Secretary for partnership and networking in IACM in 2019 and prompted educational activity with IACM.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

American Green Inc (OTCMKTS: ERBB) Expanded its e-commerce Presence, and Marimed Inc (OTCMKTS: MRMD) Announced the Launch of New SKUs

Published

on

American Green Inc (OTCMKTS: ERBB) announced that the corporate house had expanded its presence on eBay.com, one of the leading e-commerce platforms. In addition, the company announced that it has started selling Premium Hemp Cream and Hemp Lip Balm on the e-commerce platform. Last December, the group launched its products on Amazon.com. The company is doing well on the virtual platform. Motivated by its success, the corporate house is optimistic about matching sales or exceeding sales on eBay.com.

Company announces free shipping of its products purchased on eBay under ‘Buy it Now’ initiative

American Green Inc president David G. Gwyther went on record and shared that the group is thrilled that its range of premium hemp products is available on eBay. Gwyther informed that its range of products will be made available with eBay’s ‘Buy it Now’ initiative. Under this function, free shipping for all U.S. customers is offered. In addition, the eBay platform will give customers from across the world access to American Green Inc’s products, the president informed. The online platform eBay has more than 185 million users from across the world. Expectations are pinned high, and the company is optimistic that its products will do well on the virtual platform. 

The Online Emporium of the group is persistent in demonstrating year-on-year growth and sales of the products sold under the American Green Inc banner. The group expects more revenue to be generated in September 2021 as it considers eBay a potential income source. 

Marimed Inc (OTCMKTS: MRMD) announced the launch of new SKUs of its Betty’s Eddies brand of cannabis 

Marimed Inc (OTCMKTS: MRMD) announced the launch of its new SKUs of its top-selling Betty’s Eddies brand of cannabis. The products are infused fruit chews. In addition, the group is giving its customers the option to purchase the award-winning Betty’s Eddies brand in a pack as a single-serve pack which will be available for a low cost. The group is optimistic that this will prompt new customers to try the brand. 

The company has re-launched its multi-pack due to demand from consumers

Following the demand from customers, Marimed Inc has re-launched its multi-pack. The newly launched pack will have an assortment of the brand’s original five classic flavors, including Berry Good Things, Orange You Beautiful, O’ My Grapeness, Little Lemon Heaven, and Lime a Good Person. The recently launched multi-pack gives users to try the flavors and purchase the one they love.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Australis Capital Inc (OTCMKTS: AUSAF) to Acquire Outstanding Shares of BW Macaw Group, Inc and Professional Bull Riders Announce Multi-year Agreement

Published

on

Australis Capital Inc (OTCMKTS: AUSAF) announced that the group has recently entered into a binding sheet agreement. As per the deal, the group will acquire 100% of both issued and outstanding shares of BW Macaw Group, Inc.

BW Macaw Group, Inc (Herbs) has inked an agreement with EAZE

In the backdrop of the developments, it has come to light that Herbs has inked a distribution agreement with EAZE. The latter is the most significant legal cannabis delivery and distribution company based out of California. Besides this, the group has two contract manufacturers ready to start the production process of the company’s range of products in California. Besides holding a retail license which is a part of a contemplated transaction, it has come to light that Herbs’ business license also gives the freedom to cultivate, manufacture and distribute cannabis products.

More details about the transaction

A sum of US$5 million is the contemplation for the transaction. The amount is payable in stock. The deemed value is calculated using a 10-day volume-weighted average price (VWAP). Once the transaction is completed, it is learned that the company will issue a total of close to 22.6 million shares. The group does not intend to take any long-term debt. 

Australis Capital Inc and Professional Bull Riders Announce multi-year agreement 

Australis Capital Inc announced that the group has entered into a multi-year agreement with Professional Bull Riders. The company operates as AUDACIOUS. The partnership is official, and AUDACIOUS is named the “Official CBD of Professional Bull Riders.” The group will work closely with PBR, which is the world’s leading bull riding organization.

Launch of full PBR-endorsed line of topical CBD products on the cards

The partnership has paved the way for the launch of a full PBR-endorsed line of topical CBD products. The range of products includes pain relief and recovery products manufactured from ingredients such as menthol and lidocaine. The products will be made available as roll-on, gel, and also in spray formats. In addition, AUDACIOUS is all set to launch the new product portfolio of its CBD product line under the Wreck Relief brand name.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

Trending Stories